Florence
Laufzeit: 01.01.2012 - 31.12.2013
imported
Kurzfassung
Febuxostat for tumor lysis syndrome prevention in hematologic malignancies: a randomized, double blind, phase III study versus Allopurinol
Laufzeit: 01.01.2012 - 31.12.2013
Febuxostat for tumor lysis syndrome prevention in hematologic malignancies: a randomized, double blind, phase III study versus Allopurinol
